Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Sharplin will lead BTRU efforts to accelerate clinical translation of novel cellular therapeutics.

Kirsty Sharplin

Dr Sharplin has been appointed as the first Consultant in Advanced Cellular Therapeutics at Oxford, a post funded jointly by NHS Blood and Transplant (NHSBT), Oxford University Hospitals and the National Institute for Health and Care Research (NIHR).

Dr Sharplin trained in medicine at the University of Sydney, before completing her training in haematology in Adelaide and Bristol where she undertook a fellowship in chimeric antigen receptor therapy. She has now returned to the UK to join the Oxford BTRU team. As well as looking after patients undergoing stem cell transplantation, Dr Sharplin leads the therapeutic apheresis programme and works with the British Bone Marrow Registry and Cord Blood Bank to ensure the wellbeing of stem cell donors across the UK.

By working with NHSBT and the BTRU, Dr Sharplin aims to facilitate the translation of novel cellular therapeutics into first-in-human clinical trials. This will capitalise on her skills obtained during her higher degree studies in clinical trial research with the University of Sydney.